CTOs on the Move

Frederick Memorial Healthcare System

www.fmh.org

 
Frederick Memorial Healthcare System is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Frederick Memorial Healthcare System is based in Frederick, MD. You can find more information on Frederick Memorial Healthcare System at www.fmh.org
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.fmh.org
  • 400 W 7th St
    Frederick, MD USA 21701
  • Phone: 240.566.3300

Executives

Name Title Contact Details

Similar Companies

Deering Community Health Center

Deering Community Health Center is a Billings, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ritter Natural Sciences

Ritter Natural Sciences is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Soft infotech

Soft infotech is a Clifton, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rimidi

What if one solution could change everything you thought you knew about Diabetes?

Cellanyx

Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.